pharma · Clostridium Difficile Infection · Ulcerative Colitis · MCRB
Seres Therapeutics
Seres Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2010
- Employees
- 129
- Programs
- 8
- Drugs
- 7
- Patents
- 36
Seres Therapeutics projects
8 ClinicalTrials.gov programs sponsored by Seres Therapeutics.
Seres Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
SER-109
Seres Therapeutics
Clostridioides Difficile Infection
1 trial -
SER-109
Seres Therapeutics
Clostridium Difficile Infection
1 trial -
SER-109
Seres Therapeutics
Clostridium Difficile
1 trial -
Vancomycin Pre-Treatment
Seres Therapeutics
Ulcerative Colitis
1 trial -
Placebo for antibiotic
Seres Therapeutics
Metastatic Melanoma
1 trial -
SER-262
Seres Therapeutics
Clostridium Difficile Infection
1 trial -
SER-287
Seres Therapeutics
Ulcerative Colitis
1 trial -
Vancomycin Pre-Treatment
Seres Therapeutics
Allogeneic Hematopoietic Stem Cell Transplantation
1 trial
Frequently asked questions
How many clinical projects does Seres Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.